Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-24
2007-07-24
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S094000, C546S022000, C514S233200
Reexamination Certificate
active
09566875
ABSTRACT:
The present invention relates to optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.
REFERENCES:
patent: 3924042 (1975-12-01), Gerster
patent: 3984403 (1976-10-01), Fujisawa
patent: 3985882 (1976-10-01), Gerster
patent: 4051247 (1977-09-01), Schuppan et al.
patent: 4399134 (1983-08-01), Ishikawa et al.
patent: 4404207 (1983-09-01), Stern
patent: 4416884 (1983-11-01), Ishikawa et al.
patent: 4443447 (1984-04-01), Gerster et al.
patent: 4472406 (1984-09-01), Gerster
patent: 4472407 (1984-09-01), Stern
patent: 4535161 (1985-08-01), Hayakawa
patent: 4552879 (1985-11-01), Ishikawa et al.
patent: 4594347 (1986-06-01), Ishikawa et al.
patent: 4599418 (1986-07-01), Irikura et al.
patent: 4642355 (1987-02-01), Nakamura
patent: 5185337 (1993-02-01), Fujii et al.
patent: 5859026 (1999-01-01), Ito et al.
patent: 5889009 (1999-03-01), Miyake et al.
patent: 6034100 (2000-03-01), Adachi et al.
patent: 6121285 (2000-09-01), Takemura et al.
patent: 6184388 (2001-02-01), Takemura et al.
patent: 6329391 (2001-12-01), Ledoussal et al.
patent: 6750224 (2004-06-01), Patel et al.
patent: 6753333 (2004-06-01), De Souza et al.
patent: 0908181 (1999-04-01), None
patent: 57081486 (1982-05-01), None
patent: 57176987 (1982-10-01), None
patent: 63192753 (1987-02-01), None
patent: 02131483 (1988-11-01), None
patent: 02188589 (1989-01-01), None
patent: 02188570 (1990-07-01), None
patent: 05339238 (1992-06-01), None
patent: 58090511 (1992-11-01), None
Berge SM et al. Journal of Pharmaceutical Sciences. 66(1), pp. 1-19 (1977).
Morita S et al. Tetrahedron:Asymmetry. 6(1), pp. 245-254 (1995).
Bundgaard H. Design of Prodrugs. (1985). Elsevier. pp. 1-3.
Bundgaard Hans. Design of Prodrugs. 1985. Elsevier. Amsterdam-New York-Oxford. pp. 1-5.
English Abstract of Japanese Patent JP 02131483 dated Nov. 1988.
English Abstract of Japanese Patent JP 02188589 dated Jan. 1989.
Abstract: Koike, M. et al. “Metabolic Fate of (.+−.)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl) . . . Rabbits and Dogs”Iyakuhin Kenkyuvol. 21, No. 5 (1990) pp. 998-1021.
Abstract: Koike, M. et al. “Metabolic Fate of (.+−.)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl) . . . Rabbits and Dogs”Iyakuhin Kenkyuvol. 21, No. 5 (1990) pp. 1022-1033.
Abstract: Fujita, S. et al. “General Pharmacology of (.+−.)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl) . . . antibacterial agent”Iyakuhin Kenkyuvol. 21, No. 6 (1990) pp. 1156-1176.
Abstract: Koike, M. et al. “The Distribution of OPC-7251 in the Skin”Yakubutsu Dotaivol. 5, No. 2 (1990) pp. 199-208.
Abstract: Yasuo, A. et al. “Pharmacokinetics and Safety Evaluation of OPC-7251 Cream After Topical . . . Volunteers”Yakuri to Chiryovol. 18, No. 4 (1990) pp. 1717-1730.
Abstract: Hayakawa, R. et al. “Safety Evaluation of Topical OPC-7251 (Synthetic Antibacterial Agent)”Hifuvol. 32, No. 2 (1990) pp. 217-230.
Abstract: Asada, Y. et al. “Pharmacokinetics and Toxicity of OPC-7251 Cream After Topical Applications . . . Volunteers”Yakuri to Chiryovol. 18, No. 4 (1990) pp. 1717-1730.
Abstract: Awogi, T. et al. “Genotoxicity Studies of (.+−.)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidyl) . . . Antibacterial Agent”Iyakuhin Kenkyuvol. 21, No. 4 (1990) pp. 626-635.
Abstract: Matsuzawa, A. et al. “Reproductive and Developmental Toxicity Studies of (.+−.)-9-fluoro-6,7-dihydro- . . . Agent”Iyakuhin Kenkyuvol. 21, No. 4 (1990) pp. 636-646.
Abstract: Nagao, T. et al. “Reproductive and Developmental Toxicity Studies Of (.+−.)-9-fluoro-6,7-dihydro-8- . . . Administration”Iyakuhin Kenkyuvol. 21, No. 4 (1990) pp. 647-662.
Abstract: Matsuzawa, A. et al. “Reproductive and Developmental Toxicity Studies Of (.+−.)-9-fluoro- . . . Administration”Iyakuhin Kenkyuvol. 21, No. 4 (1990) pp. 663-670.
Abstract: Hashimoto, K. et al. “Acute Toxicity Study of the Synthetic Antibacterial Topical Agent (.+−.)-9-fluoro-6,7- . . . Acid (OPC-7251)”Iyakuhin Kenkyuvol. 21, No. 4 (1990) pp. 670-677.
Abstract: Furukawa, M. et al. “Primary Skin Irritation, Four-Week Cumulative Skin Irritation, . . . 1% OPC-7251 Cream”Iyakuhin Kenkyuvol. 21, No. 5 (1990) pp. 989-997.
Abstract: Kojima, K. et al. “Thirteen-Week Subcutaneous Toxicity and Four-Week Recover Tests . . . (OPC-7251) in Rats”Iyakuhin Kenkyuvol. 21, No. 5 (1990) pp. 1034-1052.
Abstract: Nakagiri, N. et al. “Contact Sensitivity, Photocontact Sensitivity And Antigenicity Tests . . . Antibacterial Agent”Iyakuhin Kenkyuvol. 21, No. 6 (1990) pp. 1144-1155.
Abstract: Aoki, M. et al. “Thirteen-Week Percutaneous Toxicity And Four-Week Recovery Tests . . . (OPC-7251) in Dogs”Iyakuhin Kenkyuvol. 21, No. 6 (1990) pp. 1177-1202.
Abstract: Matsuzawa, A. et al. “Reproductive And Developmental Toxicity Studies of . . . Administration”Iyakuhin Kenkyuvol. 22, No. 1 (1990) pp. 61-76.
Abstract: Kurokawa, I. et al. “Clinical And Bacteriologic Evaluation of OPC-7251 in Patients With Acne: . . . Cream Base”J. Am. Acad. Dermatol. vol. 25, No. 4 (1991) pp. 674-681.
Abstract: Bojar, R. A. et al. “Analysis of Resistance In The Cutaneous Microflora During Treatment Of Acne- . . . Erythromycin”J. of Investigative Dermatologyvol. 103, No. 3 (1994) pp. 405.
Abstract: Bojar, R.A. et al. “Analysis Of Resistance In The Cutaneous Microflora During Treatment . . . 2-Percent Erythromycin”J. Of Investigative Dermatologyvol. 103, No. 3 (1994) pp. 405.
Abstract: Haustein, U.F. et al. “Topical Quinolone Nadifloxacin (OPC-7251) In Bacterial Skin Disease: . . . Testing”J. of Dermatological Treatmentvol. 8, No. 2 (1997) pp. 87-92.
Abstract: Smith, C.M. et al. “Influence of Different Formulations on the Efficacy of Topical Nadifloxacin (OPC-7251)”J. of Investigative Dermatologyvol. 108, No. 3 (1997) pp. 123.
Abstract: Hayakawa, R. et al. “Skin Safety Evaluation of Nadifloxacin (OPC-7251)”Hifuvol. 40, No. 2 (1998) pp. 165-171.
Abstract: Fujio, N. et al. “Absorption, Distribution and Excretion of 14C-Labeled OPC-7251 Lotion In Rats”Yakuri to Chiryovol. 26, No. 7 (1998) pp. 1119-1132.
Hashimoto, K. et al. “A Practical Synthesis of (S)-(−)-Nadifloxacin: Novel Acid-Catalyzed Racemization . . . ”Chem. Pharm. Bull. vol. 44 No. 4 (1996) pp. 642-645.
Irish, D. et al. “Control of an Outbreak of an Epidemic Methicillin-ResistantStaphylococcus aureusalso Resistant to Mupirocin”Journal of Hospital Infectionvol. 39 (1998) pp. 19-26 (XP-000884368).
Kido, M. et al. “Crystal Structures of Nadifloxacin Anhydride and Its Hemihydrate”Chem. Pharm. Bull. vol. 42 No. 4 (1994) pp. 872-876.
Kido, M. et al. “The Absolute Configuration of (R)-(+)-Nadifloxacin”Chem. Pharm. Bull. vol. 44 No. 2 (1996) pp. 421-423.
English Abstract of Japanese Patent J05339238 Dated Jun. 1992.
English Abstract of Japanese Patent J58090511 Dated Nov. 1992.
English Abstract of Japanese Patent J63192753 Dated Feb. 1987.
English Abstract of Japanese Patent JP57081486 Dated May 1982.
English Abstract of Japanese Patent 57-176987 Dated Oct. 1982.
English Abstract of Japanese Patent 02188570 Dated Jul. 1990.
Miller, M.A. et al. “Development of Mupirocin Resistance Among Methicillin-ResistantStaphylococcus aureus . . . ” Infection Control and Hospital Epidemiologyvol. 17 No. 12 (1995) pp. 811-813 (XP-000884374).
Nishijima,
Agarwal Shivkumar
Chaturvedi Nishith Chandra
De Souza Noel John
Kandepu Sreenivas
Khorakiwala Habil Fakhruddin
Desai Rita
Ladas and Parry LLP
Wockhardt Limited
LandOfFree
Antibacterial optically pure benzoquinolizine carboxylic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibacterial optically pure benzoquinolizine carboxylic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial optically pure benzoquinolizine carboxylic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3785331